Research programme: COVID 19 antiviral therapeutics - CR Double Crane Pharmaceuticals/Ligand Pharmaceuticals
Alternative Names: BEPro-enabled COVID-19 antivirals; COVID-19 antiviral therapeutic compounds - CR Double Crane Pharmaceuticals/Ligand PharmaceuticalsLatest Information Update: 09 Dec 2021
Price :
$50 *
At a glance
- Originator CR Double-Crane Pharmaceuticals; Ligand Pharmaceuticals
- Developer Ligand Pharmaceuticals
- Class Antivirals
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical COVID 2019 infections
Most Recent Events
- 21 Oct 2021 Ligand Pharmaceuticals and China Resources Double-Crane Pharmaceutical signs R&D agreement for COVID-19 antiviral therapeutics
- 21 Oct 2021 Ligand Pharmaceuticals files patent protection for BEPro technology and COVID-19 antiviral compounds before October 2021
- 21 Oct 2021 Preclinical trials in COVID-2019 infections in USA, China (PO) before October 2021